Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Rapid Kill' Antibiotic Awaits US Data For Blanket Decolonization Prior To Surgery

This article was originally published in Scrip

Executive Summary

Destiny Pharma Ltd., a small UK antibiotic developer, and its lead "rapidly bactericidal" product XF-73, has placed itself firmly on the radar in the US. The National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH, is sponsoring and funding a clinical trial which is expected to complete in the coming weeks. If successful, XF-73 will be filed for the prevention of post-surgical Staphylococcal infections, a completely new indication. CEO Dr Bill Love explained to Scrip why the interest in Destiny's child.


Related Content





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts